The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma

INTRODUCTION Tumor-infiltrating CD8+ T cells are associated with improved clinical outcomes in non-small cell lung cancer (NSCLC). Here we studied their prognostic effect in the context of the expression of HLA molecules that are key in tumor recognition (HLA-A, B and C) or suppression of immunity (HLA-E) as this is still unknown. METHODS Tumor tissue of 197 patients with resected pulmonary adenocarcinoma was analyzed for the presence of CD8+ T cells and the expression of β2-microglobulin, HLA-A, HLA-B/C and HLA-E. The relation of these parameters with overall survival (OS) was assessed. RESULTS Loss and low expression of HLA-A or HLA-B/C was found in 44% and 75% of cases respectively. A high CD8+ tumor infiltration was strongly associated with clinical benefit only when the tumors retained good expression of HLA-A and HLA-B/C (p=0.004). In addition, more than 70% of the tumors were found to display a high expression of HLA-E. The expression of HLA-E by tumor cells was an independent negative prognostic factor for OS (p=0.031). Importantly, a dense stromal CD8+ T cell infiltration was strongly associated with improved OS only in HLA-E negative tumors (p=0.005) and its prognostic effect was completely abolished when tumors highly expressed HLA-E (p=0.989). CONCLUSIONS CD8+ T cell infiltration strongly contributes to a better prognosis in NSCLC when the tumor cells retain the expression of classical HLA class I and do not express HLA-E. Therefore, analysis of HLA-A, -B/C and HLA-E expression should be included as biomarkers to predict the response to immunotherapy.

[1]  J. Ahn,et al.  Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.

[2]  David C. Smith,et al.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[4]  S. Natsugoe,et al.  Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer. , 2015, Anticancer research.

[5]  W. Liang,et al.  Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. , 2015, Journal of thoracic disease.

[6]  H. An,et al.  Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. , 2015, Journal of thoracic disease.

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  R. Herbst,et al.  Objective measurement and clinical significance of TILs in non-small cell lung cancer. , 2015, Journal of the National Cancer Institute.

[9]  P. Validire,et al.  CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.

[10]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[11]  Nivolumab approved for lung cancer. , 2015, Cancer discovery.

[12]  S. H. van der Burg,et al.  Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV‐induced usual vulvar intraepithelial neoplasia and implications for immunotherapy , 2014, International journal of cancer.

[13]  Douglas B. Johnson,et al.  Immune Checkpoint Inhibitors in NSCLC , 2014, Current Treatment Options in Oncology.

[14]  Grazyna Kochan,et al.  Role of non-classical MHC class I molecules in cancer immunosuppression , 2013, Oncoimmunology.

[15]  F. Tanaka,et al.  Prognostic implications of human leukocyte antigen class I expression in patients who underwent surgical resection for non-small-cell lung cancer. , 2013, The Journal of surgical research.

[16]  H. Uramoto,et al.  Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer. , 2013, Anticancer research.

[17]  You-jian He,et al.  Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer , 2013, Medical Oncology.

[18]  F. Tanaka,et al.  Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients , 2013, International Journal of Clinical Oncology.

[19]  E. Jordanova,et al.  HLA-E expression in cervical adenocarcinomas: association with improved long-term survival , 2012, Journal of Translational Medicine.

[20]  C. Volteau,et al.  HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression , 2012, International journal of cancer.

[21]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[22]  J. Coebergh,et al.  Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Wenfu Zhou,et al.  HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. , 2011, Lung cancer.

[24]  S. H. van der Burg,et al.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes , 2011, Proceedings of the National Academy of Sciences.

[25]  Rafael Sirera,et al.  The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  H. Putter,et al.  HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.

[27]  T. Ottenhoff,et al.  The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. , 2010, Microbes and infection.

[28]  E. Miyaoka,et al.  Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  M. Bianchini,et al.  Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells , 2009, Innate immunity.

[30]  L. Tanoue,et al.  New TNM classification for non-small-cell lung cancer , 2009, Expert review of anticancer therapy.

[31]  E. Carosella,et al.  HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. , 2008, Human immunology.

[32]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[33]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[34]  C. Melief,et al.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.

[35]  M. Nishimura,et al.  Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. , 2008, Cancer immunity.

[36]  Hong Yang,et al.  Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. , 2007, Lung cancer.

[37]  M. Nishimura,et al.  HLA class I antigen expression is associated with a favorable prognosis in early stage non‐small cell lung cancer , 2007, Cancer science.

[38]  A. Moreau,et al.  Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells1 , 2006, The Journal of Immunology.

[39]  T. Oshikiri,et al.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.

[40]  S. Ferrone,et al.  Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? , 2006, Cancer Immunology, Immunotherapy.

[41]  B. Bellosillo,et al.  The CD94/NKG2C killer lectin‐like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells , 2005, European journal of immunology.

[42]  Anthony J Alberg,et al.  Epidemiology of lung cancer: looking to the future. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Bell,et al.  Functional characterization of HLA‐F and binding of HLA‐F tetramers to ILT2 and ILT4 receptors , 2000, European journal of immunology.

[44]  P. A. Peterson,et al.  Cell surface expression of HLA‐E: interaction with human β2‐microglobulin and allelic differences , 1999, European journal of immunology.

[45]  B. Nielsen,et al.  Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. , 1998, European journal of cancer.

[46]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.